Multiply Labs publicly announced a USD 75 million Series B on Tuesday 6 October 2026, led by Patrick Soon-Shiong with NantWorks. Fred Parietti's San Francisco team builds robotic systems for biologic drug manufacturing, integrating equipment already used in pharmaceutical laboratories. The company plans to expand manufacturing capacity, advance its product roadmap and grow its engineering, regulatory and business teams. Its clusters automate timed, repetitive steps while allowing drug manufacturers to retain control of production. The investment targets a practical constraint in medicine: manufacturing capacity must develop alongside drug discovery if new therapies are to reach patients at the required scale.
Multiply Labs raises USD 75m for robotic drug manufacturing
Patrick Soon-Shiong and NantWorks lead the Series B

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


